Qiankun Niu
Overview
Explore the profile of Qiankun Niu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
212
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shu C, Li J, Rui J, Fan D, Niu Q, Bai R, et al.
Nat Commun
. 2025 Mar;
16(1):2324.
PMID: 40057483
Harnessing the power of immune system to treat cancer has become a core clinical approach. However, rewiring of intrinsic circuitry by genomic alterations enables tumor cells to escape immune surveillance,...
2.
Ouyang W, Li Q, Niu Q, Qui M, Fu H, Du Y, et al.
J Mol Cell Biol
. 2023 Nov;
15(11).
PMID: 37968137
The transforming growth factor-beta (TGFβ) signaling pathway plays crucial roles in the establishment of an immunosuppressive tumor microenvironment, making anti-TGFβ agents a significant area of interest in cancer immunotherapy. However,...
3.
Ouyang W, Niu Q, Qui M, Fu H, Du Y, Mo X
bioRxiv
. 2023 Jul;
PMID: 37503208
The signaling pathway of transforming growth factor-beta (TGFβ) plays crucial roles in the establishment of an immunosuppressive tumor microenvironment, making anti-TGFβ agents a significant area of interest in cancer immunotherapy....
4.
Cicka D, Niu Q, Qui M, Qian K, Miller E, Fan D, et al.
J Mol Cell Biol
. 2023 Mar;
15(3).
PMID: 36921991
SARS-CoV-2, the coronavirus that causes the disease COVID-19, has claimed millions of lives over the past 2 years. This demands rapid development of effective therapeutic agents that target various phases...
5.
Mo X, Niu Q, Ivanov A, Tsang Y, Tang C, Shu C, et al.
Cell
. 2022 May;
185(11):1974-1985.e12.
PMID: 35512704
Comprehensive sequencing of patient tumors reveals genomic mutations across tumor types that enable tumorigenesis and progression. A subset of oncogenic driver mutations results in neomorphic activity where the mutant protein...
6.
Shu C, Zheng X, Wuhafu A, Cicka D, Doyle S, Niu Q, et al.
Acta Pharmacol Sin
. 2022 Jan;
43(9):2419-2428.
PMID: 35031699
Ovarian cancer is one of the most common gynecologic malignancies in women and has a poor prognosis. Taxanes are a class of standard first-line chemotherapeutic agents for the treatment of...
7.
Tang C, Niu Q, Cicka D, Du Y, Mo X, Fu H
STAR Protoc
. 2021 Sep;
2(3):100804.
PMID: 34527960
Protein-protein interactions (PPIs) have emerged as promising yet challenging therapeutic targets. A robust bioassay is required for rapid PPI modulator discovery. Here, we present a time-resolved Förster's (fluorescence) resonance energy...
8.
Tang C, Mo X, Niu Q, Wahafu A, Yang X, Qui M, et al.
Cell Chem Biol
. 2020 Dec;
28(5):636-647.e5.
PMID: 33326750
Tumor suppressor genes represent a major class of oncogenic drivers. However, direct targeting of loss-of-function tumor suppressors remains challenging. To address this gap, we explored a variant-directed chemical biology approach...
9.
Du Y, Li X, Niu Q, Mo X, Qui M, Ma T, et al.
J Mol Cell Biol
. 2020 Jul;
12(8):630-643.
PMID: 32678871
The recent advent of robust methods to grow human tissues as 3D organoids allows us to recapitulate the 3D architecture of tumors in an in vitro setting and offers a...
10.
Niu Q, Wang W, Wei Z, Byeon B, Das A, Chen B, et al.
Biochem Biophys Res Commun
. 2020 Apr;
526(2):453-458.
PMID: 32234239
The yeast ATP-dependent chromatin remodeling enzyme Fun30 has been shown to regulate heterochromatin silencing, DNA repair, transcription, and chromatin organization. Although chromatin structure has been proposed to influence splice site...